{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:37:21Z","timestamp":1794260241429,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the absence of new antimicrobial drugs being developed to replace those facing resistance, bacterial resistance continues to grow. Despite previous studies conducted in various countries, there is a lack of comprehensive local reporting on the occurrence of carbapenem resistance among gram-negative bacteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to identify the prevalence of carbapenem-resistant gram-negative bacterial isolates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A retrospective cross-sectional study was conducted at an academic hospital in Jordan over an eight-month period, spanning from November 2021 to June 2022. The study involved screening electronic medical records to identify patients with clinical cultures showing the growth of Gram-negative bacteria. Antimicrobial susceptibility results of the Gram-negative isolates were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1,043 isolated Gram-negative bacteria were analyzed for carbapenem susceptibility. Among the species tested, the most common carbapenem-resistant bacteria were\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      (153\/164, 93.3%), followed by\n                      <jats:italic>Klebsiella pneumonia<\/jats:italic>\n                      (184\/311, 59.2%), and\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (67\/160, 41.9%). The least commonly isolated species resistant to carbapenem were\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      (25\/361, 6.9%) and\n                      <jats:italic>Proteus mirabilis<\/jats:italic>\n                      (1\/30, 3.3%). None of\n                      <jats:italic>Serratia marcescens<\/jats:italic>\n                      or\n                      <jats:italic>Proteus vulgaris<\/jats:italic>\n                      isolates were resistant to carbapenem (0%). Overall, the prevalence of carbapenem-resistance gram-negative isolates was 41.2% (430 out of 1,043).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides population-specific data that are crucial for guiding empirical antimicrobial treatment decisions not only within the participating hospital but also in other nearby healthcare facilities. The results underscore the urgent need for coordinated efforts to address antibiotic resistance in Jordan. Comprehensive measures such as strict infection control methods, annual nationwide surveillance programs, and effective antimicrobial stewardship programs at the national level are imperative to reduce the overuse of broad-spectrum antibiotics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08610-4","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T05:02:37Z","timestamp":1695790957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The prevalence of Carbapenem Resistance Gram negative pathogens in a Tertiary Teaching Hospital in Jordan"],"prefix":"10.1186","volume":"23","author":[{"given":"Khawla Abu","family":"Hammour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Abu-Farha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Itani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Karout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qusai","family":"Manaseer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid Abu","family":"Hammour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"1","key":"8610_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"A Cassini","year":"2019","unstructured":"Cassini A, H\u00f6gberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56\u201366.","journal-title":"Lancet Infect Dis"},{"key":"8610_CR2","doi-asserted-by":"crossref","unstructured":"Du C, Liu J, Fikhman DA, Dong KS, Monroe MBB. Shape memory polymer foams with phenolic acid-based antioxidant and antimicrobial properties for traumatic wound healing. Front Bioeng Biotechnol. 2022;10.","DOI":"10.3389\/fbioe.2022.809361"},{"key":"8610_CR3","doi-asserted-by":"crossref","unstructured":"Alkhawaldeh R, Farha RA, Hammour KA, Alefishat E. Optimizing antimicrobial therapy in urinary tract infections: a focus on urine culture and sensitivity testing. Front Pharmacol. 2022;13.","DOI":"10.3389\/fphar.2022.1058669"},{"issue":"6","key":"8610_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jsps.2018.04.006","volume":"26","author":"KA Hammour","year":"2018","unstructured":"Hammour KA, Jalil MA, Hammour WA. An exploration of parents\u2019 knowledge, attitudes and practices towards the use of antibiotics in childhood upper respiratory tract infections in a tertiary jordanian hospital. Saudi Pharm J. 2018;26(6):780\u20135.","journal-title":"Saudi Pharm J"},{"key":"8610_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.eujim.2017.12.006","volume":"17","author":"KA Hammour","year":"2018","unstructured":"Hammour KA, Farha RA, Alsous M, Rizik M, Hammour WA. Evaluation of risk factors affecting parental knowledge and attitude toward antibiotic use in children with upper respiratory tract infections. Eur J Integr Med. 2018;17:107\u201311.","journal-title":"Eur J Integr Med"},{"issue":"1","key":"8610_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/jep.13188","volume":"26","author":"S Al-Saleh","year":"2020","unstructured":"Al-Saleh S, Abu Hammour K, Abu Hammour W. Influencing factors of knowledge, attitude, and practice regarding antibiotic use in children with upper respiratory tract infections in Dubai. J Eval Clin Pract. 2020;26(1):197\u2013202.","journal-title":"J Eval Clin Pract"},{"issue":"9","key":"8610_CR7","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.4314\/tjpr.v15i9.27","volume":"15","author":"RA Farha","year":"2016","unstructured":"Farha RA, Suyagh M, Alsakran L, Alsous M, Alefishat E. Parental views of antibiotic use in children with upper respiratory tract infections in Jordan. Trop J Pharm Res. 2016;15(9):2009\u201316.","journal-title":"Trop J Pharm Res"},{"issue":"9","key":"8610_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/antibiotics9090598","volume":"9","author":"K Abu Hammour","year":"2020","unstructured":"Abu Hammour K, Al-Heyari E, Allan A, Versporten A, Goossens H, Abu Hammour G, et al. Antimicrobial consumption and resistance in a tertiary care hospital in Jordan: results of an internet-based global point prevalence survey. Antibiotics. 2020;9(9):598.","journal-title":"Antibiotics"},{"key":"8610_CR9","doi-asserted-by":"crossref","unstructured":"Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D. Ready for a world without antibiotics? The pensi\u00e8res antibiotic resistance call to action. BioMed Central; 2012. pp. 1\u201313.","DOI":"10.1186\/2047-2994-1-11"},{"key":"8610_CR10","unstructured":"WHO. Antimicrobial resistance: global report on surveillance. World Health Organization; 2014."},{"key":"8610_CR11","first-page":"175","volume":"12","author":"KM Knapp","year":"2001","unstructured":"Knapp KM, English BK. Carbapenems. 2001;12:175\u201385.","journal-title":"Carbapenems"},{"issue":"1","key":"8610_CR12","first-page":"17","volume":"23","author":"S Datta","year":"2010","unstructured":"Datta S, Wattal C. Carbapenemase producing Gram negative bacteria in tertiary health care setting: therapeutic challenges. JIMSA. 2010;23(1):17\u201320.","journal-title":"JIMSA"},{"issue":"2","key":"8610_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3904\/kjim.2012.27.2.128","volume":"27","author":"DM Livermore","year":"2012","unstructured":"Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012;27(2):128.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"8610_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2049936115621709","volume":"3","author":"G Meletis","year":"2016","unstructured":"Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Therapeutic Adv Infect Disease. 2016;3(1):15\u201321.","journal-title":"Therapeutic Adv Infect Disease"},{"issue":"12","key":"8610_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JCM.00213-21","volume":"59","author":"R Humphries","year":"2021","unstructured":"Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100. J Clin Microbiol. 2021;59(12):10\u2013128.","journal-title":"J Clin Microbiol"},{"issue":"8","key":"8610_CR16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.cmi.2019.04.013","volume":"25","author":"E Durante-Mangoni","year":"2019","unstructured":"Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943\u201350.","journal-title":"Clin Microbiol Infect"},{"key":"8610_CR17","doi-asserted-by":"crossref","unstructured":"Jean S-S, Harnod D, Hsueh P-R. Global threat of carbapenem-resistant gram-negative bacteria. Front Cell Infect Microbiol. 2022:236.","DOI":"10.3389\/fcimb.2022.823684"},{"issue":"3","key":"8610_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/hs.2014.0088","volume":"13","author":"E Toner","year":"2015","unstructured":"Toner E, Adalja A, Gronvall GK, Cicero A, Inglesby TV. La resistencia a los antimicrobianos es una emergencia sanitaria mundial. Health Secur. 2015;13(3):153\u20135.","journal-title":"Health Secur"},{"issue":"1","key":"8610_CR19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/ijcm.IJCM_217_18","volume":"44","author":"A Dixit","year":"2019","unstructured":"Dixit A, Kumar N, Kumar S, Trigun V. Antimicrobial resistance: progress in the decade since emergence of New Delhi metallo-\u03b2-lactamase in India. Indian J Community Medicine: Official Publication Indian Association Prev Social Med. 2019;44(1):4.","journal-title":"Indian J Community Medicine: Official Publication Indian Association Prev Social Med"},{"key":"8610_CR20","doi-asserted-by":"crossref","unstructured":"Aloraifi RI, Alharthi AF, Almefleh AA, Alamri AH, Alobud AS, Bawazeer RA et al. Prevalence of carbapenem non-susceptible gram-negative bacteria at tertiary care hospitals in Saudi Arabia. Cureus. 2023;15(1).","DOI":"10.7759\/cureus.33767"},{"issue":"1","key":"8610_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-018-0430-1","volume":"7","author":"P Yang","year":"2018","unstructured":"Yang P, Chen Y, Jiang S, Shen P, Lu X, Xiao Y. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrob Resist Infect Control. 2018;7(1):1\u20137.","journal-title":"Antimicrob Resist Infect Control"},{"key":"8610_CR22","doi-asserted-by":"crossref","unstructured":"Cai B, Echols R, Magee G, Arjona Ferreira JC, Morgan G, Ariyasu M, et al. editors. Prevalence of carbapenem-resistant gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa2017 2017: Oxford University Press US.","DOI":"10.1093\/ofid\/ofx176"},{"issue":"3","key":"8610_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08610-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08610-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08610-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T03:23:06Z","timestamp":1730172186000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08610-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8610"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08610-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"14 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was designed and conducted in accordance with the guidelines outlined in the World Medical Association Declaration of Helsinki. The Institutional Review Board (IRB) of Jordan University Hospital (JUH) granted approval for the study\u2019s protocol. The conduct of this investigation adhered to JUH\u2019s code of ethics for protecting patients\u2019 rights in research studies (number 10\/2022\/17082). To safeguard patients\u2019 privacy and confidentiality, their medical records were anonymized and de-identified. The research team maintained no direct contact or follow-up with the patients. Given the retrospective observational nature of the study, where data collection occurred after patients\u2019 discharge or death, and no patient identifiers were accessed, the IRB at JUH waived the need for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"634"}}